Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.

Molecular genetics of pancreatic intraepithelial neoplasia

Open access
Feldmann, Georg, Beaty, Robert, Hruban, Ralph H., Maitra, Anirban · 2007 · Journal of Hepato-Biliary-Pancreatic Surgery

Abstract

Background Recent evidence suggests that noninvasive precursor lesions, classified as pancreatic intraepithelial neoplasia (PanIN), can progress to invasive pancreatic cancer. This review will discuss the major genetic alterations in PanIN lesions.Methods A comprehensive review of the literature was performed in order to find studies on the molecular profile of human PanIN lesions. In addition, recent publications on genetically engineered mouse models of preinvasive neoplasia and pancreatic cancers were reviewed.Results PanINs demonstrate abnormalities at the genomic (DNA), transcriptomic (RNA), and proteomic levels, and there is a progressive accumulation of molecular alterations that accompany the histological progression from low-grade PanIN-1A to high-grade PanIN-3 lesions. Molecular changes in PanINs can be classified as "early" (KRAS2 mutations, telomere shortening, p21(WAF1/CIP1) up-regulation, etc.), "intermediate" (cyclin D1 up-regulation, expression of proliferation antigens, etc.), or "late" (BRCA2 and TP53 mutations, DPC4/SMAD4/MADH4 inactivation, etc.). All the genetic changes observed in PanINs are also found in invasive ductal adenocarcinomas, where they usually occur at a higher frequency. Genetically engineered mice expressing mutant Kras in the pancreas, with or without additional genetic alterations, provide a unique in vivo platform to study the pancreatic cancer progression model.Conclusions Molecular studies have been instrumental in establishing that PanIN lesions are the noninvasive precursors for invasive ductal adenocarcinomas. The availability of molecular date provides the basis for designing rational early detection strategies and therapeutic intervention trials before pancreatic neoplasms invade, with the intention of alleviating the dismal prognosis associated with this disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00534-006-1166-5

Cites

86 of 86 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 86 references

Research works printed but not linked: 19

  1. VG Vogel, 2003, Clin Cancer Res, 9, 495S
  2. AL Cubilla, 1976, Cancer Res, 36, 2690
  3. DS Klimstra, 1994, Am J Pathol, 145, 1547
  4. CJ Sherr, 2000, Harvey Lect, 96, 73
  5. M Schutte, 1997, Cancer Res, 57, 3126
  6. T Ueki, 2000, Cancer Res, 60, 1835
  7. MS Redston, 1994, Cancer Res, 54, 3025
  8. RE Wilentz, 2000, Cancer Res, 60, 2002
  9. AP Klein, 2001, Cancer J, 7, 266
  10. GA Griffin, 1995, Cancer Res, 55, 2394
  11. AV Biankin, 2001, Cancer Res, 61, 8830
  12. S Gansauge, 1997, Cancer Res, 57, 1634
  13. ON Tucker, 1999, Cancer Res, 59, 987
  14. T Vargo-Gogola, 2002, Cancer Res, 62, 5559
  15. P Argani, 2001, Cancer Res, 61, 4320
  16. CA Iacobuzio-Donahue, 2003, Cancer Res, 63, 8614
  17. H Han, 2002, Cancer Res, 62, 2890
  18. CD Logsdon, 2003, Cancer Res, 63, 2469
  19. P Argani, 2001, Clin Cancer Res, 7, 3862

Cited by

See all 269

Metadata

Authors
Feldmann, G., Beaty, R., Hruban, R. H., & Maitra, A.
Affiliations
Johns Hopkins University (US)
Venue
Journal of Hepato-Biliary-Pancreatic Surgery
Published
2007-05-29
Volume
14
Issue
3
Pages
224-232
ISSN
  • 0944-1166 (ISSN-L)
  • 1436-0691
OpenAlex
W2011982648
Cited by
269
References
86
Citations by year
2026: 10 · 2025: 5 · 2024: 7 · 2023: 14 · 2022: 20 · 2021: 29 · 2020: 9 · 2019: 12 · 2018: 16 · 2017: 16 · 2016: 18 · 2015: 15 · 2014: 23 · 2013: 16 · 2012: 16
FWCI
5.66
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Journal of Hepato-Biliary-Pancreatic Surgery (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Cancer Institute (R01CA113669)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R21DK072532)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
Keywords
pancreatic intraepithelial neoplasia, pancreatic cancer progression, KRAS mutation, telomere shortening, p21, cyclin D1, BRCA2 mutation, TP53 mutation, genetically engineered mouse models, pancreatic ductal adenocarcinoma, early detection of pancreatic cancer, molecular alterations
MeSH terms
Animals, Carcinoma in Situ, DNA, Neoplasm, Humans, Molecular Biology, Mutation, Oncogenes, Pancreatic Neoplasms, Biomarkers, Tumor, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular genetics of pancreatic intraepithelial neoplasia. https://app.cochat.ai/papers/10.1007/s00534-006-1166-5
The paper
Feldmann, G., Beaty, R., Hruban, R. H., & Maitra, A. (2007). Molecular genetics of pancreatic intraepithelial neoplasia. Journal of Hepato-Biliary-Pancreatic Surgery. https://doi.org/10.1007/s00534-006-1166-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.